Loading...
Biosimilar therapeutics—what do we need to consider?
Patents for the first generation of approved biopharmaceuticals have either expired or are about to expire. Thus the market is opening for generic versions, referred to as ‘biosimilars’ (European Union) or ‘follow-on protein products’ (United States). Healthcare professionals need to understand the...
Saved in:
| Main Author: | |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Oxford University Press
2009
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2638545/ https://ncbi.nlm.nih.gov/pubmed/19461855 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndtplus/sfn177 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|